SLC5A2 and metabolic dysfunction-associated steatotic liver disease: ADA, American Diabetes Association; EASD, European Association for the Study of Diabetes; GLP-1, glucagon-like peptide-1; GLP-1 RA, glucagon-like peptide-1 receptor agonists; ASCVD, atherosclerotic cardiovascular disease; SGLT2, sodium-glucose cotransporter 2; BW, body weight; CV, cardiovascular; CVD, cardiovascular disease; T2DM, type 2 diabetes mellitus; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; MACE, major adverse cardiovascular events; HbA1c, glycated hemoglobin; SF-36, 36-Item Short Form Health Survey; ASCVE, atherosclerotic cardiovascular events